Financial Contrast: Hikma Pharmaceuticals (OTCMKTS:HKMPF) and Sandoz Group (OTCMKTS:SDZNY)

Sandoz Group (OTCMKTS:SDZNY) and Hikma Pharmaceuticals (OTCMKTS:HKMPF) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, risk and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings and target prices for Sandoz Group and Hikma Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sandoz Group	0	2	0	0	2.00
Hikma Pharmaceuticals	0	0	1	1	3.50

Dividends

Sandoz Group pays an annual dividend of $0.44 per share and has a dividend yield of 0.8%. Hikma Pharmaceuticals pays an annual dividend of $0.96 per share and has a dividend yield of 3.5%.

Volatility & Risk

Sandoz Group has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, Hikma Pharmaceuticals has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500.

Institutional and Insider Ownership

0.1% of Sandoz Group shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Sandoz Group and Hikma Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sandoz Group	N/A	N/A	N/A
Hikma Pharmaceuticals	N/A	N/A	N/A

Earnings & Valuation

This table compares Sandoz Group and Hikma Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sandoz Group	$10.36 billion	2.30	$1.00 million	N/A	N/A
Hikma Pharmaceuticals	$3.13 billion	1.97	$359.00 million	N/A	N/A

Hikma Pharmaceuticals has lower revenue, but higher earnings than Sandoz Group.

Summary

Hikma Pharmaceuticals beats Sandoz Group on 5 of the 9 factors compared between the two stocks.

About Sandoz Group

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.